Based on our comprehensive understanding of the cellular metabolism of the immune system, Rheos has built a pipeline of novel, differentiated drug programs that target fundamental underpinnings of immune system dysfunction while, at the same time, identifying the molecular signatures for patient subsets.
Lead Drug Program: RXH-317, A Novel MALT1 Inhibitor
RXH-317 targets MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), a protein expressed exclusively in cells of the immune system. We have shown that MALT1 activity is central to the anabolic shift that fuels pathogenic functions of immune cells, an orchestrated group of metabolic changes referred to by Rheos as the anabolic hub. As a MALT1 inhibitor, RHX-317 is designed to inhibit the activity of multiple immune cell types, attenuating the inflammatory response in the activated immune system. RXH-317 has shown efficacy in several validated models of disease, including graft-versus-host disease (GVHD) and lupus nephritis. Because of MALT1’s role in cellular metabolism, activity of RHX 317 can be monitored by metabolite signatures, opening an opportunity to monitor disease and therapeutic effect.
In December 2019, Rheos established a multi-target discovery, development, and commercialization collaboration with Roche. Our shared objective is to identify and develop new therapeutics that leverage immunometabolism to target molecular drivers of autoimmune and inflammatory diseases.
In December 2020, Rheos announced a strategic partnership with PatientsLikeMe, the world’s largest integrated community, health management, and real-world data platform. This partnership aims to investigate underlying metabolic drivers of immune-mediated disease in order to advance Rheos’ precision medicine efforts.